39135-39-2

Usage

Uses

Used in Pharmaceutical Industry:
1-AMINO-2,6-DIMETHYLPIPERIDINE is used as a reactant for the synthesis of various pharmaceutical compounds, such as hydrazones, superelectrophilic intermediates during 1,5-cyclization reactions, and amides. These synthesized compounds can be further utilized in the development of drugs for different therapeutic applications.
1-AMINO-2,6-DIMETHYLPIPERIDINE is also used as an anticonvulsant agent, which helps in the treatment of epilepsy and other seizure disorders. Its chemical structure allows it to interact with specific receptors in the brain, thereby modulating the neuronal activity and reducing the frequency and severity of seizures.
Additionally, 1-AMINO-2,6-DIMETHYLPIPERIDINE is used as an HIV entry inhibitor for the CXCR4 receptor. This application is crucial in the development of antiretroviral drugs that can prevent the human immunodeficiency virus (HIV) from entering and infecting healthy cells, thus helping to control the progression of the disease.
Used in Chemical Synthesis:
1-AMINO-2,6-DIMETHYLPIPERIDINE serves as a reactant for N-arylation reactions, which are essential in the synthesis of various organic compounds with diverse applications. These synthesized compounds can be used in different industries, such as agriculture, materials science, and the manufacturing of specialty chemicals.

InChI:InChI=1/C7H16N2/c1-6-4-3-5-7(2)9(6)8/h6-7H,3-5,8H2,1-2H3

Upstream product

• 21223-23-4 CH₂(CH₂CHCH₃)2NNH₂*BH₃ 
• 7732-18-5 water 
• 17721-95-8 N-nitroso-2,6-dimethylpiperidine 

Downstream Products

• 100875-43-2 2,6-dimethyl-N-(benzoylamino)piperidine 
• 102192-70-1 7-Chloro-1-[(E)-2,6-dimethyl-piperidin-1-ylimino]-3-(4-trifluoromethyl-phenyl)-1,3,4,10-tetrahydro-2H-acridin-9-one 
• 125142-78-1 [1-Cyclohexyl-meth-(E)-ylidene]-(2,6-dimethyl-piperidin-1-yl)-amine 
• 132932-23-1 2-((2,6-dimethylpiperidino)amino)-4-phenylbutyronitrile 
• 65131-00-2 2,6-Dimethyl-1-(α, α, α-trifluoro-2,6-dinitro-p-toluidino)-piperidine 
• 132932-22-0 2-((2,6-dimethylpiperidino)amino)-3-phenylpropionitrile 
• 851854-99-4 5,5-dimethyl-3-(2,6-dimethyl-1-piperidylamino)-2-cyclohexen-1-one 

Relevant academic research and scientific papers

Selective reduction of N-nitroso aza-aliphatic cyclic compounds to the corresponding N-amino products using zinc dust in CO2–H2O medium

[Figure not available: see fulltext.] A new method for reduction of N-nitroso aza-aliphatic cyclic compounds employing zinc in pressurized CO2–H2O medium has been developed. H2O and NH4Cl were used as hydrogen donors, and reduction was performed under environmentally benign conditions. The presented approach allowed to obtain the respective N-amino products selectively and in excellent yields (up to 97%).

Overcoming Problems at Elaboration and Scale-up of Liquid-Phase Pd/C Mediated Catalytic Hydrogenations in Pharmaceutical Production

The practical solutions for scale-up and production of intermediates or precursors of pharmaceuticals by liquid-phase Pd/C mediated hydrogenation can be of considerable interest and deserve broader attention even if they have not been the focus of previously published research due to regulations of patent law. The practical obstacles are persistent and have been known for a long time, but for the most part remained unpublished. The most important discoveries and solutions that contributed to the successful scale-up of hydrogenations for pharmaceutical production were the following: (i) the poisoning of Pd/C catalyst with Fe2+ ions for the selective hydrogenation of 2,6-dimethyl-1-nitrosopiperidine to the corresponding hydrazo compound; (ii) alloying of the deposited Pd metal with Cu for converting the aromatic acid chlorides into the corresponding aldehydes; (iii) alteration of the pH of the reaction mixture to basic values which enhanced the stereoselectivity of paracetamol hydrogenation; (iv) a useful modification of the catalyst preparation process, i.e., the acidification of the catalyst resulted in the hydrogenolysis of benzylic OH in a molecule containing a basic N atom; (v) use of two liquid phases, altogether a four-phase system, which permitted the hydrogenolysis of the S-S bond in a potential catalyst poisoning molecule; (vi) the preservation of the metallic Pd surface of the catalyst by saturation of the reaction mixture with hydrogen, resulting in a high H2/substrate ratio, increased the aldehyde yield in the hydrogenation of 4-chloro-butyric-acid-chloride by avoiding the unwanted poisoning effect of the hydrochloric acid. In the present article, these problems and their solutions, as they emerged during the scale-up of the processes, will be discussed in detail.